These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36527437)

  • 1. Federated analyses of multiple data sources in drug safety studies.
    Gedeborg R; Igl W; Svennblad B; Wilén P; Delcoigne B; Michaëlsson K; Ljung R; Feltelius N
    Pharmacoepidemiol Drug Saf; 2023 Mar; 32(3):279-286. PubMed ID: 36527437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Security and privacy requirements for a multi-institutional cancer research data grid: an interview-based study.
    Manion FJ; Robbins RJ; Weems WA; Crowley RS
    BMC Med Inform Decis Mak; 2009 Jun; 9():31. PubMed ID: 19527521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of the MID-NET
    Yamaguchi M; Inomata S; Harada S; Matsuzaki Y; Kawaguchi M; Ujibe M; Kishiba M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Takahashi F; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1395-1404. PubMed ID: 31464008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data harmonization and federated analysis of population-based studies: the BioSHaRE project.
    Doiron D; Burton P; Marcon Y; Gaye A; Wolffenbuttel BHR; Perola M; Stolk RP; Foco L; Minelli C; Waldenberger M; Holle R; Kvaløy K; Hillege HL; Tassé AM; Ferretti V; Fortier I
    Emerg Themes Epidemiol; 2013 Nov; 10(1):12. PubMed ID: 24257327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coping with interoperability in the development of a federated research infrastructure: achievements, challenges and recommendations from the JA-InfAct.
    González-García J; Estupiñán-Romero F; Tellería-Orriols C; González-Galindo J; Palmieri L; Faragalli A; Pristās I; Vuković J; Misinš J; Zile I; Bernal-Delgado E;
    Arch Public Health; 2021 Dec; 79(1):221. PubMed ID: 34879872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decentralized Distributed Multi-institutional PET Image Segmentation Using a Federated Deep Learning Framework.
    Shiri I; Vafaei Sadr A; Amini M; Salimi Y; Sanaat A; Akhavanallaf A; Razeghi B; Ferdowsi S; Saberi A; Arabi H; Becker M; Voloshynovskiy S; Gündüz D; Rahmim A; Zaidi H
    Clin Nucl Med; 2022 Jul; 47(7):606-617. PubMed ID: 35442222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utilization and challenges of Japan's MID-NET
    Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning From Others Without Sacrificing Privacy: Simulation Comparing Centralized and Federated Machine Learning on Mobile Health Data.
    Liu JC; Goetz J; Sen S; Tewari A
    JMIR Mhealth Uhealth; 2021 Mar; 9(3):e23728. PubMed ID: 33783362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Adverse Drug Reactions on Distributed Health Data using Federated Learning.
    Choudhury O; Park Y; Salonidis T; Gkoulalas-Divanis A; Sylla I; Das AK
    AMIA Annu Symp Proc; 2019; 2019():313-322. PubMed ID: 32308824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IV Studies: Some Insights, Clarifications, and Issues.
    Cesana BM; Biganzoli EM
    Curr Clin Pharmacol; 2018; 13(1):14-20. PubMed ID: 29651962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Language Processing and Its Implications for the Future of Medication Safety: A Narrative Review of Recent Advances and Challenges.
    Wong A; Plasek JM; Montecalvo SP; Zhou L
    Pharmacotherapy; 2018 Aug; 38(8):822-841. PubMed ID: 29884988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.